Core Viewpoint - A securities fraud class action lawsuit has been initiated against Snowflake Inc., with a deadline for potential lead plaintiffs set for April 27, 2026 [1][3][4]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of California on behalf of investors who purchased or acquired Snowflake Class A common stock between June 27, 2023, and February 28, 2024, alleging violations of the Securities Exchange Act of 1934 [4]. - The allegations include misrepresentations made by the defendants regarding customer usage and new developments related to Snowflake's products [5]. Group 2: Participation Information - Investors who wish to join the class action or discuss their legal rights can contact the Investor Relations Manager, Peter Allocco, or visit the designated website [2][8]. - All representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur any fees or expenses unless there is a recovery [3].

Core Viewpoint - A securities fraud class action lawsuit has been initiated against Corcept Therapeutics Incorporated, with a deadline for potential lead plaintiffs to file papers by April 21, 2026 [1][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of California on behalf of investors who purchased or acquired Corcept common stock between October 31, 2024, and December 30, 2025, alleging violations of the Securities Exchange Act of 1934 [4]. - The allegations include misrepresentations made by the defendants regarding the adequacy of clinical evidence supporting the New Drug Application for relacorilant, Corcept's lead product candidate for multiple indications, including treatment for hypercortisolism [5]. Group 2: Investor Actions - Investors who wish to participate in the class action can contact the Investor Relations Manager for more information and to discuss their legal rights and options [2][8]. - All representation in the lawsuit is on a contingency fee basis, meaning shareholders will not incur any fees or expenses unless there is a recovery [3].

Group 1 - Kyndryl Holdings, Inc. is facing a securities fraud class action lawsuit, and investors who have suffered losses are encouraged to contact Kirby McInerney LLP for assistance [1] - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is April 13, 2026, after which applications will not be considered by the court [1]

Core Viewpoint - The article discusses a class action lawsuit against uniQure N.V. related to alleged securities fraud, with a deadline for investors to seek lead plaintiff status by April 13, 2026 [1]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of investors who purchased uniQure securities between September 24, 2025, and October 31, 2025 [1]. - Allegations include that the design of uniQure's Pivotal Study was not fully approved by the FDA and that the company downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline due to additional studies [1]. Company Disclosure - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that data from Phase I/II studies of AMT-130 would be adequate for BLA submission, leading to uncertainty regarding the BLA submission timeline [1]. - Following this disclosure, uniQure's share price fell by $33.40, approximately 49.33%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [1].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against NuScale Power Corporation on behalf of investors who purchased or acquired its common stock between May 13, 2025, and November 6, 2025, alleging misrepresentations regarding a partnership with ENTRA1 Energy LLC [1][4]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made misrepresentations concerning the potential synergies from the Company's global commercialization partnership with ENTRA1 Energy LLC [4]. - Investors who wish to serve as lead plaintiff must file papers by April 20, 2026, and participation does not require serving as lead plaintiff to share in any recovery [3]. Group 2: Legal Representation - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since its inception in 1993 and has a strong track record in class action litigation [5]. - All representation in this lawsuit is on a contingency fee basis, meaning shareholders will not incur any fees or expenses [3].

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC ("KSF†) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) ("Corcept†or the "Company†), if they purchased or otherwise acquired the Company's shares between October 31, 2024 and December 30, 2025, inclusive (t ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- If you sold your Masonite International Corporation (“Masonite” or the “Company”) (NYSE:DOOR) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until April 7, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. ...

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The uniQure Class Action Lawsuit: Do you, or did you, own shares of uniQure N.V. (QURE)?Did you purchase your shares between September 24, 2025 and October 31, 2025, inclusive?Did you lose money in y ...

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Enphase Energy Inc. (“Enphase” or the “Company”) (NASDAQ: ENPH) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The Enphase Energy Class Action Litigation? Do you, or did you, own shares of Enphase Energy, Inc. (NASDAQ: ENPH)?Did you purchase your shares between April 22, 2025 and October 28, 2025, incl ...

Core Viewpoint - Kyndryl Holdings, Inc. is facing a securities fraud class action lawsuit due to alleged misrepresentations regarding its internal controls, affecting investors who purchased securities between August 7, 2024, and February 9, 2025 [5]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Eastern District of New York on behalf of investors who acquired Kyndryl securities during the specified period [5]. - The allegations include violations of the Securities Exchange Act of 1934 against Kyndryl and certain senior officers [5]. Group 2: Legal Actions and Deadlines - Investors wishing to serve as lead plaintiffs must file necessary documents by April 13, 2026 [4]. - Participation as a lead plaintiff is not required to share in any potential recovery from the lawsuit [4]. Group 3: Investor Information - Investors who purchased Kyndryl securities and wish to discuss their legal rights can contact the Investor Relations Manager, Peter Allocco [3][8]. - The law firm representing the investors, Bernstein Liebhard LLP, operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless there is a recovery [4][6].